A Systematic Study of Retinal Structure and Function in Diabetic Macular Oedema
Launched by QUEEN'S UNIVERSITY, BELFAST · Aug 22, 2016
Trial Information
Current as of July 21, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- Group 1 (Healthy controls without DM):
- • Persons older than 18 years without DM
- • Fundus free of any signs of retinal disease
- • Best Corrected Visual Acuity of 20/40 (73 ETDRS letters) in both eyes
- Group 2 (Persons with DM with no retinopathy):
- • Persons with Type 1 or type 2 diabetes older than 18 years
- • Normal fundus, Absence of features of DR or DMO in both eyes
- • Best Corrected Visual Acuity 20/40 (73 ETDRS letters) in at least one eye
- Group 3:
- • Persons with Type 1 or type 2 diabetes 18 years and older
- • Fundus signs of mild, moderate or severe DR and or DMO
- • Best Corrected Visual Acuity 20/200 (33 ETDRS letters) or better
- Exclusion Criteria:
- • Recent ocular surgical procedures performed within the previous 3 months
- • Presence of ocular confounding disorders such as neovascular age related macular degeneration, glaucoma or active uveitis
- • Serious life threatening conditions that would preclude attendance in the longitudinal part of the study
- • Neurological conditions that can impair vision
About Queen's University, Belfast
Queen's University Belfast is a prestigious research institution located in Northern Ireland, renowned for its commitment to advancing knowledge and improving health outcomes through innovative clinical research. The university actively engages in a diverse range of clinical trials, focusing on translational medicine and interdisciplinary collaboration to address pressing health challenges. With a strong emphasis on ethical standards and patient safety, Queen's University Belfast leverages its state-of-the-art facilities and a team of experienced researchers to contribute to the development of new therapies and enhance the understanding of various medical conditions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Belfast, , United Kingdom
Patients applied
Trial Officials
Prof Usha Chakravarthy, Phd FRCopth
Principal Investigator
Queens University Belfast
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials